MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation

Molecular Carcinogenesis

Volumn 52, Issue 2, 2013, Pages 144-154

  Allott, Emma H ^a   Lysaght, Joanne ^a   Cathcart, Mary Clare ^a   Donohoe, Claire L ^a   Cummins, Robert ^b   McGarrigle, Sarah A ^c   Kay, Elaine ^b   Reynolds, John V ^a,c   Pidgeon, Graham P ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Adipose tissue; Invasion; Obesity associated cancer; Pro tumour

Indexed keywords

GELATINASE A; GELATINASE B; PROTEIN P53;

ADIPOSE TISSUE; ARTICLE; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OBESITY, ABDOMINAL; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84872611787     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21840     Document Type: Article

References (44)

1. Harrington J, Perry I, Lutomski J, et al. SLÁN 2007: Survey of Lifestyle, Attitudes and Nutrition in Ireland. Dietary Habits of the Irish Population, Department of Health and Children. Dublin: The Stationery Office; 2008.
2. The National Cholesterol Education Program (NCEP). Executive summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
4. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
5. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-1586.
6. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: Insights from in vivo and in vitro studies. Acta Physiol Scand 2005; 183: 13-30.
7. The International Diabetes Federation. The IDF consensus: Worldwide definition of the metabolic syndrome 2006. http://www.idf.org/webdata/docs/MetS_def_update2006.pdf.
8. Corley DA, Kubo A, Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 2007; 56: 756-762.
9. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007; 133: 403-411.
10. Beddy P, Howard J, McMahon C, et al. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg 2010; 97: 1028-1034.
11. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
12. National Cancer Registry, Ireland. Incidence, Mortality, Treatment and Survival 1994-2007. http://www.ncri.ie/data.cgi/choose-methods.php.
13. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 352-358.
14. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 2007; 14: 977-991.
15. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
16. Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. Bioessays 2005; 27: 1181-1191.
17. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 87: 287-297.
18. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-8234.
19. Gu ZD, Li JY, Li M, et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 2005; 100: 1835-1843.
20. Gu ZD, Chen KN, Li M, Gu J, Li JY. Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol 2005; 11: 871-874.
21. Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: Correlations with prognostic factors. J Cell Mol Med 2006; 10: 499-510.
22. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008; 122: 2050-2056.
23. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: Metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38: 613-618.
24. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998; 77: 650-655.
25. Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 2008; 23: 693-700.
26. Itoh T, Tanioka M, Matsuda H, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999; 17: 177-181.
27. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-1051.
28. Hunter GR, Snyder SW, Kekes-Szabo T, Nicholson C, Berland L. Intra-abdominal adipose tissue values associated with risk of possessing elevated blood lipids and blood pressure. Obes Res 1994; 2: 563-568.
29. Despres JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: Implications for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6: 137-159.
30. Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 2001; 155: 197-212.
31. Zhang HH, Kumar S, Barnett AH, Eggo MC. Ceiling culture of mature human adipocytes: Use in studies of adipocyte functions. J Endocrinol 2000; 164: 119-128.
32. Ennis DP, Pidgeon GP, Millar N, Ravi N, Reynolds JV. Building a bioresource for esophageal research: Lessons from the early experience of an academic medical center. Dis Esophagus 2010; 23: 1-7.
33. Pierini R, Kroon PA, Guyot S, Ivory K, Johnson IT, Belshaw NJ. Procyanidin effects of oesophageal adenocarcinoma cells strongly depend on flavan-3-ol degree of polymerization. Mol Nutr Food Res 2008; 52: 1399-1407.
34. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
35. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: Cancer implications. Nat Rev Cancer 2009; 9: 95-107.
36. Helm J, Enkemann SA, Coppola D, Barthel JS, Kelley ST, Yeatman TJ. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res 2005; 11: 2478-2485.
37. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: Implications for ascites formation. Cancer Res 2003; 63: 5224-5229.
38. Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010; 31: 1501-1508.
39. Yu W, Liu J, Xiong X, Ai Y, Wang H. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract 2009; 205: 709-715.
40. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-1241.
41. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
42. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
43. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
44. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.